Molnupiravir maintains antiviral activity against
SARS-CoV-2 variants in vitro and in early clinical studies
IDWeek 2021 Sept 29-Oct 3
Jay A Grobler1; Julie Strizki1; Nicholas Murgolo1; Wei Gao1; Youfang Cao1; Ying Zhang1; Jiejun Du1; Manoj Nair2; Yaoxing Huang2; Yang Luo2; Daria Hazuda1; David Ho2
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA
